Categories Earnings, Health Care

Achieve Life Sciences (ACHV): Q4 2019 Earnings Snapshot

— Achieve Life Sciences (NASDAQ: ACHV) reported Q4 2019 net loss of $3.2 million, or $0.30 per share, compared to a loss of $3.6 million, or $0.55 per share, last year.   

— Total operating expenses were $3.2 million.

— At December 31, 2019, cash, cash equivalents and restricted cash was $16.7 million.

— Achieve Life Sciences completed a meeting with the US FDA to finalize the Phase 3 cytisinicline clinical development program.  

— The company established an agreement with the FreeMind Group to assist in securing non-dilutive funding to evaluate cytisinicline in vapers and e-cigarette users.  

— The company closed an underwritten public offering for gross proceeds of $13.8 million, before underwriting discounts and commissions and offering expenses.  

— ACHV shares were up 12.7% in premarket hours on Friday.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

TGT Earnings: Key quarterly highlights from Target’s Q1 2024 financial results

Target Corporation (NYSE: TGT) reported its first quarter 2024 earnings results today. Total revenue decreased 3.1% year-over-year to $24.5 billion. Comparable sales declined 3.7%. Net earnings dipped 1% to $942

Important takeaways from AutoZone’s (AZO) Q3 2024 report

Automotive parts retailer AutoZone, Inc. (NYSE: AZO) reported mixed results for the third quarter of 2024, with earnings exceeding the market’s forecast and sales missing. The management is optimistic about

What to look for when Dollar General (DG) reports Q1 2024 earnings results

Shares of Dollar General Corporation (NYSE: DG) rose over 3% on Tuesday. The stock has dropped 31% over the past 12 months. The discount retailer is scheduled to report its first

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top